Search

Your search keyword '"Schwarz LJ"' showing total 8 results
Start Over Author "Schwarz LJ" Publisher american association for cancer research (aacr)
8 results on '"Schwarz LJ"'

1. Abstract P4-01-09: Combined analysis of tissue and blood biopsies by NGS in patients with advanced breast cancer identifies targetable molecular alterations

Author

Salvador, JF, primary, Pinto, JA, additional, Araujo, JM, additional, Tirado-Hurtado, I, additional, Flores, CJ, additional, Chirinos, LA, additional, Requena, MC, additional, Carpio, S, additional, Finzel Pérez, A, additional, Aguilar, A, additional, Demol, F, additional, and Schwarz, LJ, additional

Published
2019
Full Text
View/download PDF

2. Abstract PD5-02: Not presented

Author

Guerrero-Zotano, AL, primary, Stricker, TP, additional, Hutchinson, KE, additional, Stover, DG, additional, Formisano, L, additional, Lee, K-M, additional, Schwarz, LJ, additional, Giltnane, JM, additional, Jansen, VM, additional, Gavila, J, additional, Perez-Fidalgo, A, additional, Lluch, A, additional, Llombart, A, additional, Bayar, MA, additional, Michiels, S, additional, André, F, additional, Arnedos, M, additional, Ruiz, A, additional, and Arteaga, CL, additional

Published
2018
Full Text
View/download PDF

3. Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer

Author

Formisano, L, primary, Lu, Y, additional, Jansen, VM, additional, Bauer, JA, additional, Hanker, A, additional, Gonzalez Ericsson, P, additional, Lee, K-M, additional, Nixon, MJ, additional, Guerrero-Zotano, AL, additional, Schwarz, LJ, additional, Sanders, M, additional, Sudhan, D, additional, Dugger, TC, additional, Cruz, MR, additional, Behdad, A, additional, Cristofanilli, M, additional, Bardia, A, additional, O'Shaughnessy, J, additional, Mayer, IA, additional, and Arteaga, CL, additional

Published
2018
Full Text
View/download PDF

4. Abstract P1-13-08: Extended adjuvant neratinib/fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ tumors following treatment with chemotherapy and anti-HER2 therapy

Author

Sudhan, DR, primary, Schwarz, LJ, additional, Guerrero-Zotano, AL, additional, Nixon, M, additional, Formisano, L, additional, Croessmann, S, additional, Gonzalez Ericsson, PI, additional, Sanders, ME, additional, Balko, JM, additional, Avogadri-Connors, F, additional, Cutler, RE, additional, Lalani, AS, additional, Bryce, R, additional, Auerbach, A, additional, and Arteaga, CL, additional

Published
2018
Full Text
View/download PDF

5. Abstract P6-12-09: Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression

Author

Schwarz, LJ, primary, Hutchinson, KE, additional, Estrada, MV, additional, Sanders, ME, additional, Dugger, TC, additional, Formisano, L, additional, Guerrero, AL, additional, Red-Brewer, M, additional, Young, CD, additional, Lantto, J, additional, Pedersen, MW, additional, Kragh, M, additional, Horak, ID, additional, and Arteaga, CL, additional

Published
2017
Full Text
View/download PDF

6. Abstract S6-01: JAK2 amplifications are enriched in triple negative breast cancers (TNBCs) after neoadjuvant chemotherapy and predict poor prognosis

Author

Balko, JM, primary, Giltnane, JM, additional, Schwarz, LJ, additional, Sanders, ME, additional, Wang, K, additional, Harris, LN, additional, Lin, NU, additional, Miller, VA, additional, Stephens, PJ, additional, Yelensky, R, additional, Pinto, JA, additional, Gomez, H, additional, and Arteaga, CL, additional

Published
2013
Full Text
View/download PDF

8. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

Author

Mellissa J. Nixon, Sarah Croessmann, Justin M. Balko, Carlos L. Arteaga, Paula Gonzalez Ericsson, Alshad S. Lalani, Melinda E. Sanders, Dhivya R. Sudhan, Francesca Avogadri-Connors, Angel Guerrero-Zotano, Alan Auerbach, Richard Bryce, Luigi Formisano, Luis J. Schwarz, Richard E. Cutler, Sudhan, Dr, Schwarz, Lj, Guerrero-Zotano, A, Formisano, L, Nixon, Mj, Croessmann, S, González Ericsson, Pi, Sanders, M, Balko, Jm1, Avogadri-Connors, F, Cutler, Re, Lalani, A, Bryce, R, Auerbach, A, and Arteaga, Cl.

Subjects
0301 basic medicine, Cancer Research, Receptor, ErbB-2, Breast Neoplasms, Article, Mice, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Cyclin D1, Trastuzumab, ErbB, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Adjuvant therapy, Animals, Humans, skin and connective tissue diseases, Fulvestrant, business.industry, Immunohistochemistry, Xenograft Model Antitumor Assays, Disease Models, Animal, Treatment Outcome, 030104 developmental biology, Receptors, Estrogen, Oncology, Paclitaxel, chemistry, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Neratinib, Quinolines, Cancer research, Female, Pertuzumab, business, medicine.drug
Abstract

Purpose:The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater in patients with ER+/HER2+ tumors. We thus sought to discover mechanisms that may explain the benefit from extended adjuvant therapy with neratinib.Experimental Design: Mice with established ER+/HER2+ MDA-MB-361 tumors were treated with paclitaxel plus trastuzumab ± pertuzumab for 4 weeks, and then randomized to fulvestrant ± neratinib treatment. The benefit from neratinib was evaluated by performing gene expression analysis for 196 ER targets, ER transcriptional reporter assays, and cell-cycle analyses.Results:Mice receiving “extended adjuvant” therapy with fulvestrant/neratinib maintained a complete response, whereas those treated with fulvestrant relapsed rapidly. In three ER+/HER2+ cell lines (MDA-MB-361, BT-474, UACC-893) but not in ER+/HER2− MCF7 cells, treatment with neratinib induced ER reporter transcriptional activity, whereas treatment with fulvestrant resulted in increased HER2 and EGFR phosphorylation, suggesting compensatory reciprocal crosstalk between the ER and ERBB RTK pathways. ER transcriptional reporter assays, gene expression, and immunoblot analyses showed that treatment with neratinib/fulvestrant, but not fulvestrant, potently inhibited growth and downregulated ER reporter activity, P-AKT, P-ERK, and cyclin D1 levels. Finally, similar to neratinib, genetic and pharmacologic inactivation of cyclin D1 enhanced fulvestrant action against ER+/HER2+ breast cancer cells.Conclusions:These data suggest that ER blockade leads to reactivation of ERBB RTKs and thus extended ERBB blockade is necessary to achieve durable clinical outcomes in patients with ER+/HER2+ breast cancer.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results